ArticlePlasmonics (Norwell, Mass.)
Optimizing Nanoplasmonic Biosensor Sensitivity with Orientated Single Domain Antibodies.
Article in Plasmonics (Norwell, Mass.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Expression, purification and characterization of SARS-CoV-2 spike RBD in ExpiCHO cells.Protein expression and purification · 2022Article
- Selection and Characterization of Anti-Dengue NS1 Single Domain Antibodies.Scientific reports · 2018Article
- Selection of Single-Domain Antibodies towards Western Equine Encephalitis Virus.Antibodies (Basel, Switzerland) · 2018Article
- Article
- Selection, characterization, and thermal stabilization of llama single domain antibodies towards Ebola virus glycoprotein.Microbial cell factories · 2017Article
- Improving biosensing activity to carcinoembryonic antigen with orientated single domain antibodies.Heliyon · 2017Article
- Conjugation of biotin-coated luminescent quantum dots with single domain antibody-rhizavidin fusions.Biotechnology reports (Amsterdam, Netherlands) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Localized surface plasmon resonance (LSPR) spectroscopy and imaging are emerging biosensor technologies which tout label-free biomolecule detection at the nanoscale and ease of integration with standard microscopy setups. The applicability of these techniques can be limited by the restrictions that surface-conjugated ligands must be both sufficiently small and orientated to meet analyte sensitivity requirements. We demonstrate that orientated single domain antibodies (sdAb) can optimize nanoplasmonic sensitivity by comparing three anti-ricin sdAb constructs to biotin-neutravidin, a model system for small and highly orientated ligand studies. LSPR imaging of electrostatically orientated sdAb exhibited a ricin sensitivity equivalent to that of the biotinylated LSPR biosensors for neutravidin. These results, combined with the facts that sdAb are highly stable and readily produced in bacteria and yeast, build a compelling case for the increased utilization of sdAbs in nanoplasmonic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.